The prognosis of diffuse panbronchiolitis (DPB) has been remarkably improve
d after the development of low-dose erythromycin therapy, possibly due to a
nti-inflammatory rather than anti-infective mechanisms. Interestingly, DPB
associated with lung cancer is quite rare. Here, we report an autopsy case
of DPB who developed lung cancer after a long successful therapy with low-d
ose erythromycin.